Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $18.53M fell 32.7% year over year, behind the -19.9% change in trailing-twelve-month operating expenses. Sequentially, it fell 25.1% from the prior quarter. Over 3 fiscal years it compounded at -10.1% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -32.7% toward the trailing-twelve-month pace of -19.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 84.9M USD
- Year-over-year change
- -21.0%
- 4-year CAGR
- +5.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 84.9M | -21.0% |
| FY2024 | 2024-12-31 | 107.48M | -12.3% |
| FY2023 | 2023-12-31 | 122.51M | +4.8% |
| FY2022 | 2022-12-31 | 116.91M | +70.0% |
| FY2021 | 2021-12-31 | 68.78M | — |
Operating Expenses vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 operating expenses of $86.18M is the 9th highest of the 11 companies compared; the peer median is $99.25M.
- Its year-over-year change of -19.9% is the 8th highest of 11, against a peer median of -9.3%.
- Operating expenses amounts to 38304.0% of revenue for TNYA, versus a peer median of 645.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $140.97M | +26.8% | +7.2% | 1258.3% | |
| LTM Mar 2026 | $128.39M | -22.9% | -11.4% | 185.5% | |
| LTM Mar 2026 | $100.47M | -31.6% | -2.4% | 600.9% | |
| LTM Mar 2026 | $100.3M | +45.7% | +21.8% | 689.8% | |
| LTM Mar 2026 | $99.7M | -6.6% | -8.1% | 719.4% | |
| LTM Mar 2026 | $98.8M | -9.8% | +5.9% | 4900.7% | |
| LTM Mar 2026 | $95.79M | +126.8% | +68.5% | 262.5% | |
| LTM Mar 2026 | $87.05M | -28.0% | -7.0% | 308.4% | |
| LTM Mar 2026 | $86.18M | -19.9% | -10.1% | 38304.0% | |
| LTM Mar 2026 | $61.05M | -11.7% | +0.1% | — | |
| LTM Mar 2026 | $58.43M | -8.8% | +4.2% | — | |
| Peer median (excluding TNYA) | $99.25M | -9.3% | +2.1% | 645.4% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.